Fish & Richardson Trademark & Copyright Thoughts

APRIL 1, 2022

In their Law360 Expert Analysis article, principals Kenneth Darby and Josh Griswold discuss the state of USPTO Director review since the Supreme Court’s decision in Arthrex. Arthrex Inc. Ascend Performance Materials Operations v. 1, 2021, Ascend Performance Materials Operations LLC v. ”[15].

Patent 52

Patent Art Technology Law 52

LexBlog IP

AUGUST 15, 2023

After the Supreme Court’s decision in United States v. Arthrex, Inc. , In doing so, the Director removed the “precedential” designation from an earlier POP panel in Proppant Express Investments, LLC v. Oren Techs., LLC , Case No.

Patent Application 52

Patent Application Patent Designs Design 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 7, 2022

While there was significant excitement early in the year about how the Supreme Court would rule in Arthrex , its decision in June mostly maintained the status quo. Director Review Post- Arthrex. Director Review Post- Arthrex. On June 21, 2021, the Supreme Court decided the highly anticipated Arthrex case. Arthrex, Inc.,

Reporting 52

Reporting Art Invention Patent 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

With respect to commercial launches, the United States saw fewer new biosimilars entering the market in 2021 than in previous years. 1 Mylan’s Semglee ® , which had previously launched in August 31, 2020, 2 became the first interchangeable biosimilar on the United Stated market in November 2021. Neulasta ® (Amgen).

Litigation 52

Litigation Settlement Patent Marketing 52